Tweets
One situation I've seen MSK ultrasound have impact ++ in the real-world is showing patients their own RA disease activity.
Arthritis might be the invisible disease sometimes, but seeing it in full Doppler colour on screen means a lot to many.
#ACR24 MSK USS Guidance @RheumNow https://t.co/wd9s6FAfp4
David Liew @drdavidliew ( View Tweet )
1 year 2 months ago
A framework for critical conversations with patients
(because the big decisions deserve high quality counselling, otherwise the consequences are real)
#ACR24 16S17 @RheumNow https://t.co/fiwYY1DuMq
David Liew @drdavidliew ( View Tweet )
1 year 2 months ago
"Do not fear RPF." - John Stone
Retroperitoneal fibrosis certainly feels challenging at times, and radiologic features might stay even after functional improvement
but we've come a long way
(although, despite B cell depletion, there's plenty more to do)
#ACR24 16S26 @RheumNow https://t.co/2Y3buXrAFY
David Liew @drdavidliew ( View Tweet )
1 year 2 months ago
The @ACRheum RA outcome measures toolkit has all the relevant tools for measuring outcomes in rheumatoid arthritis (and exactly how to do it).
https://t.co/GZ7tZ6fNMK
Great for all US rheumatologists, but also very handy for all of us globally
#ACR24 16S30 @JYazdany @RheumNow https://t.co/MSHA353MKR
Links:
David Liew @drdavidliew ( View Tweet )
1 year 2 months ago
Abstract 333 showed that in a cohort of patients with IIM-ILD increased age, PH, FVC decline at 1 yr, SOB at 2 years were predictors for mortality and lung transplant ! #ACR24 @RheumNow https://t.co/NgOj7WKeE3
Gabriela Martinez Zayas, MD @MartinezZayasMd ( View Tweet )
1 year 2 months ago
Factors associated w/ secukinumab response in PsA?
Analysis of 2.7k pt in EuroSpA
Associated w/ favorable response
❗️elevated CRP >10 mg/L
❗️fewer prev tx
Associated w/ lower response:
❗️smoking
❗️higher patient global score / HAQ
@RheumNow #ACR24 Abstr 2325
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
1 year 2 months ago
RheumNow Day 1 Recap: ACR Convergence 2024 Highlights https://t.co/xjCMpzXhTE
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 2 months ago
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush @RheumNow ( View Tweet )
1 year 2 months ago
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/DZrM5aQpJ7 https://t.co/CkGP6H8J6x
Dr. John Cush @RheumNow ( View Tweet )
1 year 2 months ago
Real shame to see a fair few withdrawn oral presentations on #ACR24 schedule. Surely there is a better way? I'm sure a fellow would have loved to have the opportunity to present their project as an oral, even at short notice. @RheumNow
Richard Conway @RichardPAConway ( View Tweet )
1 year 2 months ago
Systematic review & meta-analysis by DrHChaudhary et al @DaoudAnsaam @mmagrey1
showed that males w/ axSpA who were treated with biologics had ⬆️ BASDAI150 response & likely w/ ASDAS low dse activity vs. females w/axSpA
Again, effect of gender differences
@RheumNow #ACR24 abs599 https://t.co/2DPYC8exES
sheila @RHEUMarampa ( View Tweet )
1 year 2 months ago
New data to guide role of long-term, low dose GC in GPA
Active GPA s/p tx -> randomized to d/c pred within 1 mo or stay on 5mg daily
Fewer relapses on 5mg pred but w/qualifications:
👉 most flares = minor
👉 no difference in flares if RTX on board
@RheumNow #ACR24 Abst 0774 https://t.co/Jvc40QWLqM
Links:
Brian Jaros, MD @Dr_Brian_MD ( View Tweet )
1 year 2 months ago
